Gamma-aminobutyric acid type A receptor (benzodiazepine-sensitive subtype) (GABA-A receptor (BZD site))

Gamma-aminobutyric acid type A (GABA-A) receptor is a pentameric ligand-gated chloride ion channel predominantly expressed in the central nervous system. The benzodiazepine-sensitive GABA-A receptor contains a high-affinity allosteric site at the interface of its α and γ subunits. This site selectively binds benzodiazepine drugs, enhancing the receptor's inhibition of neuronal activity by increasing chloride influx and hyperpolarizing the neuron. The receptor is made up of various possible subunit combinations (typically 2 α, 2 β, 1 γ), creating functionally and pharmacologically distinct isoforms. It mediates the fast component of inhibitory neurotransmission (phasic inhibition) when activated by endogenous GABA, and it also underlies tonic inhibition by responding to ambient GABA levels. Dysfunction or altered modulation of GABA-A benzodiazepine receptors is implicated in numerous CNS disorders, making it a major therapeutic target for anxiolytics, hypnotics, anticonvulsants, and muscle relaxants. Drug binding at the benzodiazepine site is crucial for the clinical effects and safety profile of many psychoactive agents.

Other names

GABA-A receptorBenzodiazepine receptorGABA-benzodiazepine receptor complexGamma-aminobutyric acid type A receptorGABA-A benzodiazepine site

Positive allosteric modulation: Benzodiazepines bind at the α/γ subunit interface, enhancing the frequency of chloride channel opening in response to GABA, resulting in increased inhibitory effect. Direct agonism: Drugs such as muscimol activate the receptor by binding to the GABA site. Antagonism: Flumazenil competitively inhibits benzodiazepine binding at the receptor.